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Abstract
Background: Toddalia asiatica of Rutaceae, a Taiwan folk medicine, is used as an analgesic and anti-inﬂammatory herb.
Cyclohexylamine (CHA) is an active compound from T. asiatica. Previous reports indicate CHA contracts rat vas deferens. However, the contractile mechanism of CHA on rat vas deferens was not yet reported. The purpose of this study
was to investigate the contractile mechanism of CHA on rat epididymal portion of vas deferens.
Methods: Male S.D. rats weighting between 200 g to 250 g were used. The epididymal portion of vas deferens was
isolated and was added with various concentrations of serotonin, serotonin antagonists and CHA.
Results: Serotonin elicited dose-dependent (1 £ 10¡7M~1 £ 10¡4M) contractions on rat epididymal vas deferens, which
were inhibited by pretreatment with ketanserin (1 £ 10¡8 M ~ 1 £ 10¡6 M), methysergide (1 £ 10¡5 M) and propranolol
(1 £ 10¡4 M), respectively. CHA elicited dose-dependent (1 £ 10¡8M~1 £ 10¡4M) contractions on rat epididymal vas
deferens. The contractions of CHA (1 £ 10¡4M) on epididymal vas deferens were enhanced by serotonin in a dosedependent manner. Methysergide (1 £ 10¡7 ~1 £ 10¡5 M) did not affect the contractions evoked by CHA. However, the
CHA elicited contraction was almost completely inhibited by ketanserin (1 £ 10¡5 M) and was enhanced by propranolol.
The effect of propranolol at the concentration of 1 £ 10¡4 M on CHA was likely as CHA at high concentration alone.
Conclusions: From the above results, the contraction evoked by CHA on the isolated rat epididymal vas deferens might
be mediated by serotonergic receptors through 5-HT2A subtype.
Keywords: Cyclohexylamine, primary, Serotonergic receptors, Isolated rat epididymal vas deferens, Serotonin 5-HT2A
subtype

1. Introduction

T

oddalia asiatica L. (Rutaceae) (Fig. 1) is used
as an analgesic and anti-inﬂammatory herb
in Taiwan folk medicine. It processes many
pharmacological activities, such as anti-platelet
aggregation [1], contraction of ilea strip and aortal
strip of rat [2], anti-inﬂammatory and anti-oxidant
activities [3], induction of differentiation and
apoptosis in U937 leukemic cells [4], antimalarial
effect [5]. It also processes antinociceptive and
anti-inﬂammatory
effects
[6],
enhances

differentiation and lipolysis of adipocytes [7].
Besides, it processes antimicrobial and antifungal
activities [8,9,10], and anti-diabetic activity [11],
analgesia for central and peripheral pain management [12]. According to our preliminary data,
the methanolic extract of T. asiatica L. (250 mg/kg)
does have anti-inﬂammatory and analgesic effects. The potency is equivalent to 100 mg/kg
naproxen (unpublished data).
The active compounds from T. asiatica L. are
cyclohexylamine, toddanone, brailin, dl-syringaresinol and isopimpinellin[13]. The pharmacological

Received 21 January 2020; accepted 6 March 2020.
Available online 5 June, 2020
* Corresponding author at: Department of Pharmacology, School of Medicine, China Medical University, No. 91, Hsueh-Shih Road, Taichung, 40404.
Taiwan.
E-mail address: yfchen@mail.cmu.edu.tw (Y.-F. Chen).
https://doi.org/10.37796/2211-8039.1025
2211-8020/Published by China Medical University 2020. © the Author(s). This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).

Y.-F. CHEN ET AL
CYCLOHEXYLAMINE, AN ACTIVE COMPOUND

13

enhanced CHA-induced contractions. The interactions between 5-HT and CHA on rat epididymal vas deferens were not yet reported. Thus, the
present study aimed to investigate the relationships
between CHA- and serotonergic nervous system
induced-contraction on rat epididymal vas deferens.

2. Materials and methods
2.1. Materials

Fig. 1. Photograph of Toddalia asiatica L. Rutaceous plant.

studies of these active ingredients reveal that
cyclohexylamine (CHA) can induce contractions
and enhance the norepinephrine-induced contraction on rat epididymal vas deferens. It reveals that
CHA-induced contraction on rat epididymal vas
deferens may be related to the regulation of the
sympathetic nervous system (unpublished data).
The CHA-induced contractions of rat epididymal
vas deferens was blocked by phenoxybenzamine (an
a1-adrenoceptor antagonist) and was not changed
by ganglion blockade, bilateral adrenalectomy, or
nephrectomy and persisted in decerebrate and spinal cats [14,15].
Serotonin (5-HT) receptors presented on rat vas
deferens [16,17]. In our preliminary study, 5-HT

Cyclohexylamine was purchased from Wako,
Japan. Ketanserin tartrate and methysergide maleate were purchased from Tocris, USA. Serotonin
and propranolol were bought from Sigma-Aldrich,
USA. All drugs were dissolved in millipore water.
The composition of Kreb's solution is expressed as
follows (mM/L): NaCl 119; NaHCO3 24.9; D-Glucose
11; KH2PO4 1.2; KCl 4.6; MgSO4∙7H2O 1.2;
CaCl2∙2H2O 1.5.
2.2. Ethics statement and preparations of isolated
rat epididymal vas deferens
Male Sprague Dawley (SD) rats weighing between
200 and 250 g were purchased from National Laboratory Animal Center (NLAC), Taipei. Animals were
fed with standard chow and housed in standard cages
at a constant room temperature of 22 ± 1 C. Relative
humidity 55 ± 5% with 12 h inverted light-dark cycle
for at least one week prior to the experiment. The

Fig. 2. Effects of different concentrations of serotonin (5-HT) on cyclohexylamine (CHA) induced contraction of the isolated epididymal vas deferens of
rats. Fig. 2A represented the contraction trace of isolated rat epididymal vas deferens. The contraction force (g) change in CHA and serotonin pretreatment in Fig. 2B. With increasing concentration of 5-HT (1  10 7M ~1  10 4M) showed a dose-dependent potentiation on CHA (1  10 4M)induced contraction of the isolated epididymal vas deferens of rats (P < 0.05~P < 0.001).
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intraperitoneal injection of 50 mg/kg of zoletil® and
sacriﬁced by cervical dislocation. The vas deferens
were removed and cleaned of the surrounding connective tissue and blood vessels. Only the epididymal
portions (0.6 - 1 cm) of vas deferens were used. The
tissues were mounted into 5 ml Magnus-organ baths
containing Kreb's solution at 37 C and bubbled with
95% O2/5% CO2. Preparations were loaded with 1.5 g
resting tension, and then Kreb's solution was
refreshed every 10 min. Preparations were equilibrated for 1 hr.
2.3. Effects of different concentrations of serotonin
(5-HT) on cyclohexylamine (CHA)-induced
contraction of the isolated epididymal vas deferens
of rats

Fig. 3. Effects of 5-HT2/5-HT1C serotonergic antagonist, methysergide,
on the contraction of the isolated epididymal vas deferens of rats
induced by CHA. Different concentrations of methysergide (1  10 7M
~1  10 5 M) did not have any statistically signiﬁcant effect on the
CHA (1  10 4M)-induced isolated epididymal vas deferens of rats.

experimental protocol was approved by the Institutional Animal Care and Use Committee (IACUC),
China Medical University (permit number: 2019-332).
Male SD rats were deeply anesthetized by an

Different concentrations of 5-HT (1  10 7
M~1  10 4M) was administered ten minutes before
CHA (1  10 4M) administration, observed and
recorded the effect of 5-HT on the CHA-induced
contraction of the epididymal vas deferens of rats.
2.4. Effects of 5-HT2/5-HT1C serotonergic
antagonist on the CHA-induced contraction of the
isolated epididymal vas deferens of rats
Different
concentrations
of
methysergide
(1  10 7 M~1  10 5M) or ketanserin (1  10 8M~
1  10 6M) was administered ten minutes before
CHA (1  10 4M) administration, observed and

Fig. 4. Effects of 5-HT2/5-HT1C serotonergic antagonist, ketanserin, on the CHA-induced contraction of the isolated epididymal vas deferens of rats.
Fig. 4A represented the contraction trace of isolated rat epididymal vas deferens and the contraction force (g) change in CHA and ketaserin pretreatment in Fig. 4B (P < 0.05~P < 0.001). The CHA-induced contraction of epididymal vas deferens was completely inhibited by ketanserin at the
concentration of 1  10 5 M.
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Fig. 5. Effects of 5-HT1 serotonergic antagonists on the contraction of the isolated epididymal vas deferens of rats induced by CHA. With the increase
of the time, propranolol (1  10 5M and 1  10 6M) enhances the CHA-induced contraction of the vas deferens. Fig. 5A represented the contraction
trace of isolated rat epididymal vas deferens, the frequency change (Fig. 5B), and the contraction force (g) change in CHA and propranolol pretreatment in Fig. 5C. Propranolol at the concentration of 1  10 4M showed a suppression effect on CHA-induced contraction (P < 0.01) and the
frequency of contraction increased signiﬁcantly (P < 0.01).

recorded the effect of methysergide or ketanserin on
the CHA-induced contraction of isolated epididymal vas deferens of rats.

in every ten minutes until the contractile response
returned to baseline. The next concentration
experiment was then performed.

2.5. Effects of 5-HT1 serotonergic antagonists on the
CHA-induced contraction of the isolated
epididymal vas deferens of rats

2.7. Effects of 5-HT2/5-HT1C serotonergic
antagonists on the 5-HT-induced contraction of the
isolated epididymal vas deferens of rats

Different
concentrations
of
propranolol
(1  10 6M~1  10 4M) were given in advance, and
the effect of propranolol on the CHA-induced
contraction of the isolated epididymal vas deferens
of rats was observed and recorded.

Ten minutes before 5-HT (1  10 5M) administration, different concentrations of ketanserin
(1  10 8M~1  10 6M) or methysergide
(1  10 7M~1  10 5M) was added to the organ
bath. The effects of ketanserin or methysergide on
the 5-HT-induced contraction of the isolated
epididymal vas deferens of rats were recorded.

2.6. Effects of different concentrations of 5-HT on
the isolated epididymal vas deferens of rats
Different
concentrations
of
5-HT
(1  10 7M~1  10 4M) were administered and the
contraction of vas deferens was observed and
recorded. Twenty minutes later, the drug was
washed out and replaced with fresh Krebs solution

2.8. Effects of 5-HT1 serotonergic antagonists on the
5-HT-induced contraction of the isolated
epididymal vas deferens of rats
Ten minutes before 5-HT (1  10 5M) administration, different concentrations of propranolol
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Fig. 6. Effects of different concentrations of 5-HT on the isolated epididymal vas deferens of rats. 5-HT (1  10 7M~1  10 4M) showed a dosedependent increase in the contraction amplitude (6A), frequency (6B) and the contraction force (6C) of the rat epididymal vas deferens. The maximum
contraction tension was 0.17 ± 0.03, 0.54 ± 0.05, and 1.39 ± 0.09, respectively.

(1  10 6M~1  10 3M) was added to the organ
bath. The effects of propranolol on the 5-HTinduced contraction of the isolated epididymal vas
deferens of rats were recorded.
2.9. Statistical analysis
The results were expressed as mean ± S.E. The
differences between mean values were compared
using one-way ANOVA (post hoc test with Duncan's
test) or the Student t-test and were considered statistically signiﬁcant when P < 0.05.

3. Results
3.1. Effects of different concentrations of serotonin
(5-HT) on cyclohexylamine (CHA) induced
contraction of the isolated epididymal vas deferens
of rats
Data were shown in Fig. 2. With increasing concentration of 5-HT (1  10 7M ~1  10 4M) showed

a dose-dependent potentiation on CHA (1 
10 4M)-induced contraction of the isolated epididymal vas deferens of rats (P < 0.05~P < 0.001).
Fig. 2A represented the contraction trace of isolated
rat epididymal vas deferens and the contraction
force (g) change (Fig. 2B) in CHA and serotonin
pretreatment.
3.2. Effects of 5-HT2/5-HT1C serotonergic
antagonist on the contraction of the isolated
epididymal vas deferens of rats induced by CHA
Different
concentrations
of
methysergide
(1  10 7M ~1  10 5 M) did not have any statistically signiﬁcant effect on the CHA (1  10 4M)induced isolated epididymal vas deferens of rats (as
shown in Fig. 3). However, different concentrations
of ketanserin (1  10 8M~1  10 5M) had a concentration-dependent inhibitory effect on the CHA
(1  10 4M)-induced isolated epididymal vas deferens of rats (as shown in Fig. 4). Fig. 4A represented
the contraction trace of isolated rat epididymal vas
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Fig. 7. Effects of 5-HT2/5-HT1C serotonergic antagonist, ketanserin, on the contraction of the isolated epididymal vas deferens of rats induced by 5-HT.
The effect of pretreatment of different concentrations of ketanserin (1  10 8M~1  10 6M) showed a dose-dependent inhibition of 5-HT
(1  10 5M) induced contraction in amplitude (7A, 7C) and frequency (7B).

deferens and the contraction force (g) change in
CHA and ketaserin pretreatment in Fig. 4B
(P < 0.05~P < 0.001). The CHA-induced contraction
of epididymal vas deferens was completely inhibited by ketanserin at the concentration of 1  10 5 M.
3.3. Effects of 5-HT1 serotonergic antagonists on the
contraction of the isolated epididymal vas deferens
of rats induced by CHA
Results were shown in Fig. 5. Pretreatment with
different
concentrations
of
propranolol
(1  10 6M~1  10 4M) showed a concentrationdependent enhancement of CHA (1  10- 4M)induced contraction of the rat epididymal vas deferens at the ﬁrst two minutes. With the increase of
the time, propranolol (1  10 5M and 1  10 6M)
enhanced the CHA-induced contraction of the vas
deferens. However, propranolol at the concentration
of 1  10 4M showed a suppression effect on CHAinduced contraction (P < 0.01) and the frequency of
contraction increased signiﬁcantly (P < 0.01), the
results were shown in Fig. 5. Fig. 5A represented the

contraction trace of isolated rat epididymal vas
deferens, the frequency change (Fig. 5B), and the
contraction force (g) change in CHA and propranolol pretreatment in Fig. 5C.
3.4. Effects of different concentrations of 5-HT on
the isolated epididymal vas deferens of rats
As shown in Fig. 6, 5-HT (1  10 7M~1  10 4M)
showed a dose-dependent increase in the contraction amplitude (Fig. 6A), frequency (Fig. 6B) and the
contraction force (Fig. 6C) of the rat epididymal vas
deferens. The maximum contraction tension was
0.17 ± 0.03, 0.54 ± 0.05, and 1.39 ± 0.09, respectively.
However, the concentration of 5-HT at 1  10 7 M
did not contract rat epididymal vas deferens.
3.5. Effects of 5-HT2/5-HT1C serotonergic
antagonists on the contraction of the isolated
epididymal vas deferens of rats induced by 5-HT
As shown in Fig. 7, the effect of pretreatment of
different concentrations of ketanserin (1  10 8M~1 
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Fig. 8. Effects of 5-HT2/5-HT1C serotonergic antagonist, methysergide, on the contraction of the isolated epididymal vas deferens of rats induced by 5HT. Pretreatment with different concentrations of methysergide (1  10 7M~1  10 5M) showed a dose-dependent inhibition of 5-HT (1  10 5M)
induced contraction in amplitude (8A, 8C) and frequency (8B).

10 6M) showed a dose-dependent inhibition of 5-HT
(1  10 5M) induced contraction in amplitude (Fig. 7A
and C) and frequency (Fig. 7B). As shown in Fig. 8, the
effect of pretreatment of different concentrations of
methysergide (1  10 7M~1  10 5M) showed a
dose-dependent inhibition of 5-HT (1  10 5M)
induced contraction in amplitude, force (Fig. 8A and
C) and frequency (Fig. 8B).
3.6. Effects of 5-HT1 serotonergic antagonist on the
contraction of the isolated epididymal vas deferens
of rats induced by 5-HT
At a concentration of 1  10 5M, propranolol
showed a slight increase in contraction of the rat
epididymal vas deferens produced by 5-HT
(1  10 5M) (as shown in Fig. 9). However, when the
propranolol concentration is higher than 1  10 4M,
the vas deferens contraction effect produced by 5HT (1  10 5M) will be weakened, as shown in
Fig. 9. When given propranolol (1  10 3 M), the

contractile response of 5-HT was completely suppressed. In addition, the statistical analysis showed
that different concentrations of propranolol
(1  10 6M to 1  10 3M) can inhibit the frequency
of vas deferens produced by 5-HT, as shown in
Fig. 9.

4. Discussion
Cyclohexylamine (CHA) is one of the active ingredients of T. asiatica L. [13]. However, CHA is
also the main metabolite of cyclamate. Cyclamate,
an FDA approved artiﬁcial sweetener [18], will be
metabolized to CHA by entero-bacteria [19e21].
Ingestion of CHA or high dose of a mixture of
cyclamate and saccharin will induce bladder tumors in rats [22e25]. CHA acts on Sertoli cells of
the testis and causes testicular atrophy in the rat
[22]. The effects of CHA on the testis attributed to
the direct action of CHA on seminiferous epithelium [26].
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Fig. 9. Effects of 5-HT1 serotonergic antagonist, propranolol, on the contraction of the isolated epididymal vas deferens of rats induced by 5-HT. At a
concentration of 1  10 5M, propranolol showed a slight increase in contraction of the rat epididymal vas deferens produced by 5-HT (1  10 5M)
(as shown in Fig. 9). However, when the propranolol concentration is higher than 1  10 4M, the vas deferens contraction effect produced by 5-HT
(1  10 5M) will be weakened.

There are few reports on the effects of CHA on vas
deferens, and the action mechanism of CHA is not
yet precise. According to our data, the contraction
caused by CHA involved in the control of the sympathetic nervous system. CHA can directly act on
post-synaptic adrenergic a1A anda1B receptors. Besides, CHA also directly acts on presynaptic adrenal
receptors, thus releasing endogenous catecholamine. The effects of CHA on the contraction of the
epididymal vas deferens are all calcium-dependent
responses (unpublished data). Besides the role of
the sympathetic nerve, whether there are other action mechanisms also involved in this contraction of
CHA is the primary goal of this study.
Many kinds of literature indicate that there are
serotonergic receptors on the vas deferens of rats
[27e30]. Therefore, we use serotonin to observe the
contractile response of the epididymal vas deferens
produced by CHA. Serotonin enhanced the contractile response of CHA. This result suggests that

serotonergic receptors may be involved in CHAinduced contraction response of epididymal vas
deferens.
Comparing the response of noradrenaline (NA)
and 5-HT on rat vas deferens, the contractile
response caused by NA is fast, and tonic; and 5-HT
ﬁrst produces rapid contraction, accompanied by a
phasic and rhythmic contraction response (phasic
and rhythmic), followed by a tonic contraction.
Moreover, the vasoconstriction response of rats
induced by 5-HT is 15 times weaker than that of NA
[31]. Serotonin-induced contraction of vas deferens
in rats can be divided into direct and indirect responses; direct contractile responses are related to
the direct activation of tryptaminergic and aadrenergic receptors [32,33]. Serotonin is a medium
that is accepted by the presynaptic tryptaminergic
receptor, and thus promotes the release of NA from
the end of the sympathetic nerve, which causes
vasocontraction. Also, the direct contractile
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Fig.10. Proposed action mechanism of cyclohexylamine (CHA)-induced contraction of epididymal vas deferens of rat. CHA induced contraction on the
isolated rat epididymal vas deferens may be partially mediated by serotonergic neuron.

response of serotonin is also related to the mediator
of the a1-adrenoceptor. As for the indirect contraction response of serotonin, the release of NE is
involved, and this effect is the most crucial reason
for the contraction of the vas deferens [34].
The rapid contraction produced by 5-HT is mainly
mediated by the post-synaptic 5-HT2 neurokinin
receptors (5-HT2 receptors). While the part of the
tonic contraction is not only mediated by post-synaptic serotonin receptors (5-HT2 receptors) but also
related to the action of NE released from neuronal
stores [35]. However, high doses of ketanserin can
completely inhibit the contraction caused by serotonin, mainly because the 5-HT2 neurokinin receptor mediates the contraction of rat vas deferens
caused by serotonin [32,35]. In addition to the 5-HT2
neurokinn blocking effect, ketanserin also has the
activity of antagonizing a-adrenal receptors at a
high concentration [36]. Similar results founded in
our experiments that different concentrations of
ketanserin attenuated the dose-dependent reduction of serotonin-induced contraction of the vas

deferens of the epididymal vas deferens of the rat,
and ketanserin at high doses also showed complete
inhibition of serotonin. Besides, methysergide inhibits the effect of serotonin is smaller than that of
ketanserin. Methysergide has an antagonistic effect
only at high concentrations, which may be related to
the partial agonist of methysergide itself. Methysergide belongs to the 5HT2/5-HT1c neurokinin
antagonist [37], it is possible that the blocking effect
of 5-HT1c neurokinin by methysergide.
Studying the effect of serotonin on the twitchresponse contraction of the mice vas deferens produced by electrical stimulation [38], it was found
that serotonin produces a “bell-shape” concentration response curve below 10 8 M to 10 4 M. When
the concentration is 10 5 M, serotonin can achieve
the maximum contraction-enhancing effect. While
the concentration of serotonin is higher than
10 5 M, it shows a contraction-inhibitory effect.
Therefore, serotonin initially enhance the vas deferens response of mice induced by electrical stimulation [38].is because of the deactivation of the 5-

HT2 neurokinin receptors on post-synaptic sites
[32,38,39], resulting in an increased contractile
response. The inhibitory response at higher concentrations of serotonin relates to the activation of
presynaptic 5-HT1 neurokinin receptors (especially
5-HT1A neurokinamine receptors), but it is not
excluded that Results of involvement of postnatal 5HT neurokinin receptors [32].
Propranolol, a non-selective 5-HT1 neurokinin
antagonist, at low concentrations enhances the serotonin-induced contraction of epididymal vas
deferens of the rat. The inhibition of presynaptic 5HT1 neurokinin receptors may enhance the contractile effect of post-synaptic 5-HT2 neurokinin receptors. The reason why high doses of propranolol
completely inhibit the contractile response produced by serotonin is not known, and further
investigation is needed. Perhaps, there may be other
mechanisms (such as b-sympathetic receptors)
that are also involved in serotonin's effect on isolated rat contractile response of the epididymal vas
deferens.
However, neither the selective 5-HT2 antagonist LY 53857 nor the non-selective 5-HT antagonist -1NP could block the vas deferens caused by serotonin [34]. Thus, the contractile effect of serotonin is
mainly mediated by a-adrenergic receptors, not by
serotonergic receptors. However, the role of serotonin is not excluded for NE is released from neurons and results in a contractile response [34].
Although the actual contraction mechanism of
serotonin induced vas deferens is still controversial,
its mechanism is mainly related to the mediator of
the post-synaptic neurokinin receptor combined
with NE that released from nerve terminal. In our
experiments, different concentrations of 5-HT2/5HT1c neurokinin antagonist-ketanserin produced
the dose-dependent inhibition of CHA-induced
contractile responses of the rat epididymal vas deferens. It revealed the effect of cyclohexylamine is
related to the regulation of neurokinin receptors.
Ketanserin is a selective 5-HT2A neurokinin antagonist [40], and neurokinin involves in CHA-induced
contraction, especially the 5-HT2A neurokinin receptor. However, the involvement of neurokinin
receptors in the CHA-induced contraction may also
be an indirect effect. Because different concentrations of methysergide, 5-HT2/5-HT1c neurokinin
antagonist, do not affect the response of CHA.
Propranolol can enhance the contraction of CHA at
concentrations of 1  10 6 M and 1  10 5 M, but at
the concentration of 1  10 4 M appears to suppress
the contraction amplitude of CHA. However, the
effect of increased contraction frequency can only be
deduced that perhaps the effect of cyclohexylamine
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on the contraction of the epididymal vas deferens
may also be related to the 5-HT1c neurokinin receptors and b-sympathetic receptors.

5. Conclusions
From the above results, CHA induced contraction
on the isolated rat epididymal vas deferens might be
mediated by serotonergic receptors especially
through 5-HT2A subtype. The proposed action
mechanism of cyclohexylamine (CHA)-induced
contraction on epididymal vas deferens of rat shows
in Fig. 10).
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